Cenderitide - Mayo Clinic
Alternative Names: CD-NPLatest Information Update: 02 Oct 2021
At a glance
- Originator Mayo Clinic
- Developer Capricor Therapeutics
- Class Cardiovascular therapies; Heart failure therapies; Natriuretic peptides
- Mechanism of Action Atrial natriuretic factor receptor A agonists; Atrial natriuretic factor receptor B agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute heart failure; Chronic heart failure; Myocardial infarction
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Chronic-heart-failure in USA (SC, Injection)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Myocardial-infarction in USA (IV, Infusion)
- 16 Feb 2017 Capricor Therapeutics has elected to terminate its license agreement with the Mayo Clinic for natriuretic peptide receptor agonists, including Cenderitide